Quick Facts The world class research of Wilmot Cancer Center clinicians and scientists continues to grow and lead to new discoveries. Our team is studying techniques to detect disease earlier, to introduce new treatments that are less invasive, and to improve life after cancer. The Wilmot Cancer Center’s approach to care and research allows doctors and scientists from many areas to play an active role in providing the best possible care today and in the future. This multidisciplinary model has become the gold standard for cancer care. And the Wilmot Cancer Center is the only center in Rochester that offers this model in the major cancer sites. Quick Facts Technology developed by our physicians led to the development of vaccines against human papillomavirus, which causes nearly all cases of cervical cancer in women. The first vaccine was approved in 2006, and another vaccine is in the final stages of testing. Wilmot physicians and scientists conduct nearly $20 million in National Cancer Institute-funded research each year. The Wilmot Cancer Center provides care for 10,000 people each year, with approximately 19,000 infusions of life-saving chemotherapy and 20,000 therapeutic radiation treatments. Last year, more than 500 patients at the James P. Wilmot Cancer Center enrolled in 160 local and national clinical trials testing the latest therapies. Wilmot Cancer Center’s Samuel E. Durand Blood and Marrow Transplant Program is New York state’s second largest, performing more than 120 transplants per year. Our 100-day-survival-rates in all categories for bone marrow and stem cell transplants exceed national benchmarks. The Wilmot Cancer Center is an approved center of excellence for the evaluation and treatment of myelodysplastic syndrome. The Wilmot Cancer Center was the first upstate cancer center to introduce laparoscopic prostatectomy and the first to apply robotic technology to the procedure. Wilmot Cancer Center is home to the radiation oncology experts who were the first to take new, life-saving brain cancer treatment—shaped-beam radiosurgery—and apply it to other cancers that have spread to the lungs and other organs. Early radiation work at the Medical Center, including the pioneering research of Dr. Phillip Rubin, formed the foundation for the field of Radiation Oncology. The Wilmot Cancer Center was a national leader in creating an integrated geriatric oncology fellowship program that teaches doctors how the unique physical, psychological and social issues that face older cancer patients shape treatment decisions. The Center’s Geriatric Oncology Program is one of just a handful in the country and one of just three on the east coast. Wilmot scientists lead a group of hundreds of researchers in 22 affiliated research sites nationwide to help develop ways to minimize or eliminate side effects of cancer treatment through a National Cancer Institute effort known as the Community Clinical Oncology Program. Wilmot urologists and scientists have conducted some of the largest studies measuring the effectiveness of hormone therapy on men treated for prostate cancer. Scientists at Wilmot were first to create software that improves precision when placing radioactive seeds to treat prostate cancer. The system is called Prostate Implant Planning Engine for Radiotherapy and the team is now designing a robotic system to further advance accuracy. The Wilmot Cancer Center trains more oncologists than any other upstate New York institution. Our cancer program was one of eight URMC specialties ranked in the top 25% of nearly 5,000 eligible hospitals in the 2011 U.S. News & World Report Best Regional Hospitals listing. The Wilmot Cancer Center was recognized as one of the Top 70 in the Nation by Becker’s Hospital Review, joining the ranks of the Cleveland Clinic, Dana- Farber, Duke University, the Mayo Clinic and M.D. Anderson. Construction of a three-story vertical expansion was completed in July 2012, allowing for the relocation of some inpatient care units to the cancer center as well as additional space for our growing research programs. This addition will transform the current outpatient and research center into a comprehensive cancer hospital, offering patients a full continuum of care. There is a burgeoning scientific collaboration between the James P. Wilmot Cancer Center and Roswell Park Cancer Institute. The goal of the collaboration between upstate New York’s two largest cancer research facilities is to create a scientific powerhouse, enhancing faculty recruitment, funding, and the development of larger research studies. Donor support totaling $2 million dollars has enabled a first round of seed funding that is being used to fund the studies of eight collaborative teams of scientists from each institution. This unique alliance is expected to lead to discoveries that will improve patient care and fuel further research. Accreditations Accreditation by the American College of Surgeons Commission on Cancer as a Teaching Hospital Cancer Program. The Comprehensive Breast Care Center at the James P. Wilmot Cancer Center has achieved the status of Certified Quality Breast Center of Excellence through a quality initiative of the National Consortium of Breast Care Centers, joining a list of just 27 other centers nationwide. Center of Excellence for Breast Imaging by the American College of Radiology. This prestigious three-year-accreditation is the pinnacle of recognition, as the Center already holds designation for its breast ultrasound, mammography, and stereotactic breast biopsy services. The Comprehensive Breast Care Center’s three-year/full accreditation designation by the National Accreditation Program for Breast Centers, a program administered by the American College of Surgeons. The Center is one of only 12 such accredited institutions in New York State and the only one in the greater Rochester and Western New York regions. The Hematology/Oncology division of the University of Rochester Medical Center’s James P. Wilmot Cancer center has earned certification through the Quality Oncology Practice Initiative (QOPI®) sponsored by the American Society of Clinical Oncology, or ASCO. The Wilmot Cancer Center joins just 121 other oncology practices and hospitals throughout the U.S. – including just eight in New York State - to achieve such certification. The Foundation for the Accreditation of Cellular Therapy (FACT) has awarded re-accreditation to the James P. Wilmot Cancer Center's Samuel E. Durand Blood and Marrow Transplantation (BMT) Program. The program performs more than 130 transplants for adults and children each year and is the second largest program in New York State, behind only Memorial Sloan-Kettering Cancer Center. The award extends the program’s accreditation through December 2014.